<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">11465869</PMID>
        <DateCompleted>
            <Year>2001</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0012-6667</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>61</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2001</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Drugs</Title>
                <ISOAbbreviation>Drugs</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intraperitoneal drug delivery of antineoplastics.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1057-65</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The administration of antineoplastic agents directly into the peritoneal cavity as treatment of localised cancer is based on sound pharmacokinetic principles. This unique technique has to the potential to optimise outcome in settings where preclinical and clinical data suggest that cytotoxicity of a specific drug against a particular tumour type is enhanced by either increasing the drug concentration or duration of exposure. Phase I trials have confirmed the safety and pharmacokinetic advantage for a number of agents delivered by the intraperitoneal relative to the systemic route, including cisplatin (10- to 20-fold advantage for regional delivery), carboplatin (10- to 20-fold advantage), and paclitaxel (1,000-fold advantage). In phase II trials, performed mostly in patients with ovarian cancer, this approach has achieved objective responses in settings where intravenous drug delivery has not achieved the desired effect (e.g. surgically documented complete response using intraperitoneal cisplatin as second-line therapy of ovarian cancer). Phase III trials employing intraperitoneal cisplatin as initial treatment of small volume advanced ovarian cancer have demonstrated that regional therapy results in a modest, but statistically significant, improvement in both progression-free and overall survival compared to intravenous cisplatin. Further exploration of this novel method of treatment, including the conduct of definitive randomised phase III clinical trials, is indicated in ovarian cancer and in other tumour types where clinical manifestations are principally localised to the peritoneal cavity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Markman</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA. markmam@ccf.org</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Drugs</MedlineTA>
            <NlmUniqueID>7600076</NlmUniqueID>
            <ISSNLinking>0012-6667</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007263" MajorTopicYN="N">Infusions, Parenteral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>47</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>24</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>24</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11465869</ArticleId>
            <ArticleId IdType="doi">10.2165/00003495-200161080-00003</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Gynecol Oncol. 1993 Aug;50(2):191-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8375734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 1991;28(3):159-65</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1855272</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1992 Sep;10(9):1479-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1517791</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1982 Oct;42(10):4265-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7105021</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1997 Nov;15(11):3399-407</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9363872</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Crit Rev Oncol Hematol. 1993 Feb;14(1):15-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8373538</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1981 Sep;41(9 Pt 1):3495-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7260912</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Invest. 1995;13(6):625-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7583714</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1993 Jul;50(1):100-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8349150</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 1988;21(1):57-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3277734</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1979 Aug;39(8):3209-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">455305</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Aug;16(8):2620-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9704711</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rep. 1978 Jan;62(1):1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">626987</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1996 Dec 26;335(26):1950-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8960474</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1980 Oct;40(10):3665-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7438049</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1996 Feb;14(2):343-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8636742</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1998 May 16;351(9114):1451-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9605801</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1994 Mar 15;73(6):1693-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7512437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1993 Nov 18;329(21):1550-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8155119</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 1989 Jun 15;49(12):3380-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2720692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Med Assoc. 1955 Dec 31;159(18):1704-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">13271133</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Cancer Res Clin Oncol. 1992;118(7):547-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1624547</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 1997 Apr 2;89(7):480-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9086004</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 1986;18(3):235-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3542268</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1999 Oct;75(1):10-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10502418</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1995 Dec;13(12):2961-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8523061</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1992 Apr;45(1):3-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1601332</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Surgery. 1985 Sep;98(3):414-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3898450</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1987 Oct;5(10):1607-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2443622</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rep. 1983 Mar;67(3):235-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6682012</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer. 1986 Jul 1;58(1):18-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3708543</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 1996 Jan 4;334(1):1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7494563</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Dis Colon Rectum. 1993 Apr;36(4):323-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8458256</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Crit Rev Oncol Hematol. 1999 Aug;31(3):239-46</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10532198</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 1992 Mar 14;339(8794):629-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1347336</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 1988 Jun;15(3 Suppl 4):27-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3134695</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1992 Sep;10(9):1485-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1355523</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1997 Oct;67(1):39-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9345354</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1998 Aug;16(8):2733-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9704725</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1998 Apr;69(1):17-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9570993</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Intern Med. 1982 Dec;97(6):845-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6890785</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1991 Oct;9(10):1801-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1919630</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 1990 Jan;8(1):146-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2295905</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Semin Oncol. 1985 Sep;12(3 Suppl 4):38-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3931226</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2001 Feb 15;19(4):1001-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11181662</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 1984;13(2):131-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">6467498</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Surg. 1998 Sep;228(3):347-54</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9742917</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
